Risk stratification and short-term prognosis in acute heart failure syndromes: A review of novel biomarkers

Biomarkers

Volumn 16, Issue 5, 2011, Pages 379-392

  Avellino, Ariadne ^a   Collins, Sean P ^a   Fermann, Gregory J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarkers; Heart failure; Risk stratification

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CYSTATIN C; ENDOTHELIN 1; NEUROHORMONE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROADRENOMEDULLIN; SOLUBLE ST2 RECEPTOR; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; CELL STRESS; CLINICAL DECISION MAKING; EXTRACELLULAR MATRIX; HEART MUSCLE CELL; HORMONAL REGULATION; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; OXIDATIVE STRESS; PROGNOSIS; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

ACUTE DISEASE; BIOLOGICAL MARKERS; EXTRACELLULAR MATRIX; HEART FAILURE; HUMANS; INFLAMMATION; KIDNEY; OXIDATIVE STRESS; PROGNOSIS; STRESS, PHYSIOLOGICAL;

EID: 79960786335     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.574234     Document Type: Review

References (158)

1. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. (2006). Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 47:1615-1621.
2. Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH. (2010). Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail 16:49-54.
3. Ali F, Rauf MA, Washington B, Ghali JK. (2007). Conivaptan: A dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev 25:261-279. (Pubitemid 47547465)
4. Amir O, Rogowski O, David M, Lahat N, Wolf R, Lewis BS. (2010). Circulating interleukin-10: Association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha. Isr Med Assoc J 12:158-162.
5. Ando M, Yamamoto T, Hino A, Sato T, Nakamura Y, Matsuzaki M. (2010). Norepinephrine spillover during exercise as a novel parameter to evaluate the severity of heart failure. J Nucl Cardiol 17: 868-873.
6. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Tomas JD, Topol EJ, Hazen SL, Penn MS. (2003). Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 197:615-624. (Pubitemid 36314656)
7. Banerjee I, Fuseler JW, Intwala AR, Baudino TA. (2009). IL-6 loss causes ventricular dysfunction, fbrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. Am J Physiol Heart Circ Physiol 296:H1694-H1704.
8. Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore SA, Januzzi JL Jr. (2010). Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Terapy (PROTECT) Study. Am Heart J 159:532-538.e1.
9. Beltowski, J, Wojcicka G. (2002). Regulation of renal tubular sodium transport by cardiac natriuretic peptides: two decades of research. Med Sci Monit 8:RA39-RA52. (Pubitemid 34218479)
10. Binkley PF, Nunziata E, Haas GJ, Nelson SD, Cody RJ. (1991). Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: Demonstration in human subjects and verifcation in a paced canine model of ventricular failure. J Am Coll Cardiol 18:464-472.
11. Bisping E, Tenderich G, Barckhausen P, Stumme B, Bruns S, von Lewinski D, Pieske B. (2007). Atrial myocardium is the predominant inotropic target of adrenomedullin in the human heart. Am J Physiol Heart Circ Physiol 293:H3001-H3007. (Pubitemid 350110313)
12. Blum A. (2009). Heart failure-new insights. Isr Med Assoc J 11:105-111.
13. Bolignano D, Coppolino G, Lacquaniti A, Buemi M. (2010). From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confnes of nephrology. Eur J Clin Invest 40:273-276.
14. Braunwald E. (2008). Biomarkers in heart failure. N Engl J Med 358:2148-2159.
15. Brower GL, Gardner JD, Forman MF, Murray DB, Voloshenyuk T, Levick SP, Janicki JS. (2006). The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 30:604-610. (Pubitemid 44332949)
16. Bu DX, Hemdahl AL, Gabrielsen A, Fuxe J, Zhu C, Eriksson P, Yan ZQ. (2006). Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-κB. Am J Pathol 169:2245-2253. (Pubitemid 351181982)
17. Bui AL, Horwich TB, Fonarow GC. (2011). Epidemiology and risk profle of heart failure. Nat Rev Cardiol 8:30-41.
18. Burkhardt H, Bojarsky G, Gladisch R. (2002). Diagnostic efciency of cystatin C and serum creatinine as markers of reduced glomerular fltration rate in the elderly. Clin Chem Lab Med 40:1135-1138. (Pubitemid 36024448)
19. Buralli S, Dini FL, Ballo P, Conti U, Fontanive P, Duranti E, Metelli MR, Marzilli M, Taddei S. (2010). Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure. Am J Cardiol 105:853-856.
20. Burnett JC Jr. (2005). Urocortin: Advancing the neurohumoral hypothesis of heart failure. Circulation 112:3544-3546.
21. Carrasco Sánchez FJ. (2011). Galectin-3-independent prognosis in heart failure. Clin Res Cardiol 100:183.
22. Cawley MJ. (2007). Hyponatremia: Current treatment strategies and the role of vasopressin antagonists. Ann Pharmacother 41:840-850. (Pubitemid 46752663)
23. Chaudhary K, Phadke G, Nistala R, Weidmeyer CE, McFarlane SI, Whaley-Connell A. (2010). The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep 10:37-42.
24. Chiao YA, Jin YF, Lindsey ML. (2010). Tipping the extracellular matrix balance during heart failure progression: Do we always go right? Cardiology 116:130-132.
25. Christenson RH, Duh SH, Wu AH, Smith A, Abel G, deFilippi CR, Wang S, Adourian A, Adiletto C, Gardiner P. (2010). Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin Biochem 43:683-690.
26. Cicoira M, Rossi A, Bonapace S, Zanolla L, Golia G, Franceschini L, Caruso B, Marino PN, Zardini P. (2004). Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 10:403-411. (Pubitemid 41080221)
27. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. (1992). Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85:504-509.
28. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. (1984). Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819-823. (Pubitemid 14035089)
29. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. (2008). Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 10:997-1000.
30. Davenport A, Anker SD, Mebazaa A, Palazzuoli A, Vescovo G, Bellomo R, Ponikowski P, Anand I, Aspromonte N, Bagshaw S, Berl T, Bobek I, Cruz DN, Daliento L, Haapio M, Hillege H, House A, Katz N, Maisel A, Mankad S, McCullough P, Ronco F, Shaw A, Sheinfeld G, Soni S, Zamperetti N, Zanco P, Ronco C; Acute Dialysis Quality Initiative (ADQI) consensus group. (2010). ADQI 7: The clinical management of the Cardio-Renal syndromes: Work group statements from the 7th ADQI consensus conference. Nephrol Dial Transplant 25:2077-2089.
31. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. (2009). Galectin-3: A novel mediator of heart failure development and progression. Eur J Heart Fail 11:811-817.
32. de Sa DD, Chen HH. (2008). The role of natriuretic peptides in heart failure. Curr Cardiol Rep 10:182-189.
33. Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T. (2009). Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 95:1508-1513.
34. Djoussé L, Kurth T, Gaziano JM. (2008). Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J 155:82-86. (Pubitemid 350234775)
35. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. (2000). The prognostic implications of renal insufciency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35:681-689. (Pubitemid 30167025)
36. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, Castro L, Lusis AJ, Nauseef WM, White CR, Freeman BA. (2002). Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296:2391-2394. (Pubitemid 34734213)
37. Finkel T. (1999). Signal transduction by reactive oxygen species in non-phagocytic cells. J Leukoc Biol 65:337-340. (Pubitemid 29109705)
38. Floras JS. (1993). Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol 22:72A-84A. (Pubitemid 23285800)
39. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. (1984). The neurohumoral axis in congestive heart failure. Ann Intern Med 101:370-377. (Pubitemid 14033790)
40. Frantz S, Störk S, Michels K, Eigenthaler M, Ertl G, Bauersachs J, Angermann CE. (2008). Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: An independent predictor of mortality. Eur J Heart Fail 10:388-395.
41. Gheorghiade M, Gottlieb SS, Udelson JE, Konstam MA, Czerwiec F, Ouyang J, Orlandi C; Tolvaptan Investigators. (2006). Vasopressin v(2) receptor blockade with tolvaptan versus fuid restriction in the treatment of hyponatremia. Am J Cardiol 97:1064-1067.
42. Goetze JP. (2004). Biochemistry of pro-B-type natriuretic peptide-derived peptides: The endocrine heart revisited. Clin Chem 50:1503-1510. (Pubitemid 39121217)
43. Goldsmith SR. (2006). The role of vasopressin in congestive heart failure. Cleve Clin J Med 73 Suppl 3:S19-S23.
44. Gray GA, Webb DJ. (1996). The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ter 72:109-148. (Pubitemid 26423301)
45. Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, Ostergren J, Lonn E. (2008). Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol 102:733-737.
46. Grieve DJ, Shah AM. (2003). Oxidative stress in heart failure. More than just damage. Eur Heart J 24:2161-2163. (Pubitemid 37522667)
47. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, Hlavin P, Maisel AS. (2002). B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39:131-138. (Pubitemid 34118942)
48. Hokamaki J, Kawano H, Yoshimura M, Soejima H, Miyamoto S, Kajiwara I, Kojima S, Sakamoto T, Sugiyama S, Hirai N, Shimomura H, Nagayoshi Y, Tsujita K, Shioji I, Sasaki S, Ogawa H. (2004). Urinary biopyrrins levels are elevated in relation to severity of heart failure. J Am Coll Cardiol 43:1880-1885. (Pubitemid 38622530)
49. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW; American College of Cardiology Foundation; American Heart Association. (2009). 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53:e1-e90.
50. Ishiyama Y, Kitamura K, Ichiki Y, Nakamura S, Kida O, Kangawa K, Eto T. (1993). Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. Eur J Pharmacol 241:271-273. (Pubitemid 23272891)
51. Januzzi JL Jr, Peacock W F, Maisel AS, Chae CU, Jesse RL, Baggish AL, O'Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowski KB, Lloyd-Jones DM, Wu AH. (2007). Measurement of the interleukin family member ST2 in patients with acute dyspnea: Results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 50:607-613. (Pubitemid 47199007)
52. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. (2006). NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J 27:330-337. (Pubitemid 43100029)
53. Jensen J, Ma LP, Fu ML, Svaninger D, Lundberg PA, Hammarsten O. (2010). Infammation increases NT-proBNP and the NT-proBNP/ BNP ratio. Clin Res Cardiol 99:445-452.
54. Jensen LT, Høst NB. (1997). Collagen: Scafold for repair or execution. Cardiovasc Res 33:535-539.
55. Jougasaki M, Stevens TL, Borgeson DD, Luchner A, Redfeld MM, Burnett JC Jr. (1997). Adrenomedullin in experimental congestive heart failure: Cardiorenal activation. Am J Physiol 273:R1392-R1399.
56. Jougasaki M, Wei CM, McKinley LJ, Burnett JC Jr. (1995). Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 92:286-289.
57. Jug B, Salobir BG, Vene N, Sebestjen M, Sabovic M, Keber I. (2009). Interleukin-6 is a stronger prognostic predictor than high-sensitive C-reactive protein in patients with chronic stable heart failure. Heart Vessels 24:271-276.
58. Kalogeropoulos A, Georgiopoulou V, Psaty BM, Rodondi N, Smith AL, Harrison DG, Liu Y, Hofmann U, Bauer DC, Newman AB, Kritchevsky SB, Harris TB, Butler J; Health ABC Study Investigators. (2010). Infammatory markers and incident heart failure risk in older adults: The Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol 55:2129-2137.
59. Katan M, Müller B, Christ-Crain M. (2008). Copeptin: A new and promising diagnostic and prognostic marker. Crit Care 12:117.
60. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. (1995). Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26:1257-1263.
61. Kedzierski RM, Yanagisawa M. (2001). Endothelin system: The double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41:851-876. (Pubitemid 32385909)
62. Kelly D, Squire IB, Khan SQ, Quinn P, Struck J, Morgenthaler NG, Davies JE, Ng LL. (2008). C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail 14:739-745.
63. Khaper N, Bryan S, Dhingra S, Singal R, Bajaj A, Pathak CM, Singal PK. (2010). Targeting the vicious infammation-oxidative stress cycle for the management of heart failure. Antioxid Redox Signal 13:1033-1049.
64. Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD, Suzuki T, Ebina M, Nukiwa T, Sasano H. (2002). Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 87:340-346. (Pubitemid 34084712)
65. Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, Chen A, Tung R, Januzzi JL Jr. (2005). Efect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 149:744-750.
66. Kubin AM, Skoumal R, Tavi P, Kónyi A, Perjés A, Leskinen H, Ruskoaho H, Szokodi I. (2011). Role of reactive oxygen species in the regulation of cardiac contractility. J Mol Cell Cardiol.
67. Kumar SK, Mather PJ. (2009). AVP receptor antagonists in patients with CHF. Heart Fail Rev 14:83-86.
68. La Rocca G, Di Stefano A, Eleuteri E, Anzalone R, Magno F, Corrao S, Loria T, Martorana A, Di Gangi C, Colombo M, Sansone F, Patanè F, Farina F, Rinaldi M, Cappello F, Giannuzzi P, Zummo G. (2009). Oxidative stress induces myeloperoxidase expression in endocardial endothelial cells from patients with chronic heart failure. Basic Res Cardiol 104:307-320.
69. Lainchbury JG, Troughton RW, Lewis LK, Yandle TG, Richards AM, Nicholls MG. (2000). Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers. J Clin Endocrinol Metab 85:1016-1020. (Pubitemid 32269342)
70. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP, Tognoni G, Cohn JN; Val-HeFT Investigators. (2004). The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 25:292-299. (Pubitemid 38295437)
71. Lee CR, Watkins ML, Patterson JH, Gattis W, O'connor CM, Gheorghiade M, Adams KF Jr. (2003). Vasopressin: A new target for the treatment of heart failure. Am Heart J 146:9-18. (Pubitemid 36851295)
72. Lee CS, Tkacs NC. (2008). Current concepts of neurohormonal activation in heart failure: Mediators and mechanisms. AACN Adv Crit Care 19:364-385; quiz 386.
73. Li YY, McTiernan C F, Feldman AM. (2000). Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46:214-224. (Pubitemid 30204593)
74. Lin YH, Lin C, Lo MT, Lin HJ, Wu YW, Hsu RB, Chao CL, Hsu HC, Wang PC, Wu VC, Wang SS, Lee CM, Chien KL, Ho YL, Chen MF, Peng CK. (2010). The relationship between aminoterminal propeptide of type III procollagen and heart rate variability parameters in heart failure patients: A potential serum marker to evaluate cardiac autonomic control and sudden cardiac death. Clin Chem Lab Med 48:1821-1827.
75. Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB, Chao CL, Wang SS, Hsein YC, Liao LC, Ho YL, Chen MF. (2009). The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 409:96-99.
76. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner
77. S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozafarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Tom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. (2010). Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 121:e46-e215.
78. López B, González A, Díez J. (2010). Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 121:1645-1654.
79. Lubrano V, Pingitore A, Carpi A, Iervasi G. (2010). Relationship between triiodothyronine and proinfammatory cytokines in chronic heart failure. Biomed Pharmacother 64:165-169.
80. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P, Steg G, Aumont MC, Westheim A, Knudsen CW, Perez A, Kamin R, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. (2003). Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 41:2010-2017. (Pubitemid 36677124)
81. Malemud CJ. (2006). Matrix metalloproteinases (MMPs) in health and disease: An overview. Front Biosci 11:1696-1701. (Pubitemid 43253387)
82. Mann DL. (2006). Heart failure: Beyond practice guidelines. Tex Heart Inst J 33:201-203. (Pubitemid 44299855)
83. Matsumoto M, Tsujino T, Lee-Kawabata M, Naito Y, Sakoda T, Ohyanagi M, Masuyama T. (2010). Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. Cytokine 49:264-268.
84. McCullough PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, McCord J, Herrmann HC, Steg PG, Westheim A, Knudsen CW, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS; BNP Multinational Study Investigators. (2003). Uncovering heart failure in patients with a history of pulmonary disease: Rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 10:198-204. (Pubitemid 36292619)
85. McMurray J, Stewart S. (2002). The Burden of Heart Failure. Eur Heart J Supplement D:1-9.
86. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. (1998). Clinical epidemiology of heart failure: Public and private health burden. Eur Heart J 19 Suppl P:P9-16.
87. McMurray JJ, Stewart S. (2000). Epidemiology, aetiology, and prognosis of heart failure. Heart 83:596-602. (Pubitemid 30316742)
88. Mitof PR, Gam D, Ivanov J, Al-hesayen A, Azevedo ER, Newton GE, Parker JD, Mak S. (2011). Cardiac-specifc sympathetic activation in men and women with and without heart failure. Heart 97:382-387.
89. Moran A, Katz R, Smith NL, Fried L F, Sarnak MJ, Seliger SL, Psaty B, Siscovick DS, Gottdiener JS, Shlipak MG. (2008). Cystatin C concentration as a predictor of systolic and diastolic heart failure. J Card Fail 14:19-26.
90. Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M. (2007). Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 28:219-226. (Pubitemid 47220835)
91. Morrow DA, de Lemos JA. (2007). Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115:949-952. (Pubitemid 46328287)
92. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. (2008). Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 54:752-756. (Pubitemid 351573718)
93. Mueller EE, Momen A, Massé S, Zhou YQ, Liu J, Backx PH, Henkelman RM, Nanthakumar K, Stewart DJ, Husain M. (2011). Electrical remodelling precedes heart failure in an endothelin-1-induced model of cardiomyopathy. Cardiovasc Res 89:623-633.
94. Nagase H, Woessner JF Jr. (1999). Matrix metalloproteinases. J Biol Chem 274:21491-21494. (Pubitemid 129519680)
95. Nakagomi A, Seino Y, Endoh Y, Kusama Y, Atarashi H, Mizuno K. (2010). Upregulation of monocyte proinfammatory cytokine production by C-reactive protein is signifcantly related to ongoing myocardial damage and future cardiac events in patients with chronic heart failure. J Card Fail 16:562-571.
96. Ng LL, Loke IW, O'Brien RJ, Squire IB, Davies JE. (2004). Plasma urocortin in human systolic heart failure. Clin Sci 106:383-388. (Pubitemid 38553586)
97. Nicholls SJ, Hazen SL. (2005). Myeloperoxidase and cardiovascular disease. Arterioscler Tromb Vasc Biol 25:1102-1111. (Pubitemid 40776595)
98. Nishida H, Horio T, Suzuki Y, Iwashima Y, Kamide K, Kangawa K, Kawano Y. (2008). Plasma adrenomedullin as an independent predictor of future cardiovascular events in high-risk patients: Comparison with C-reactive protein and adiponectin. Peptides 29:599-605.
99. Nishikimi T, Horio T, Kohmoto Y, Yoshihara F, Nagaya N, Inenaga T, Saito M, Teranishi M, Nakamura M, Ohrui M, Kawano Y, Matsuo H, Ishimitsu T, Takishita S, Matsuoka H, Kangawa K. (2001). Molecular forms of plasma and urinary adrenomedullin in normal, essential hypertension and chronic renal failure. J Hypertens 19:765-773. (Pubitemid 32289557)
100. Nishikimi T, Maeda N, Matsuoka H. (2006). The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69:318-328. (Pubitemid 43098788)
101. Ochieng J, Furtak V, Lukyanov P. (2004). Extracellular functions of galectin-3. Glycoconj J 19:527-535. (Pubitemid 38316526)
102. Øie E, Ahmed MS, Ueland T, Sikkeland LI, Dahl CP, Hagelin EM, von Lueder T, Edvardsen T, Andreassen AK, Gullestad L, Aukrust P, Yndestad A, Vinge LE, Attramadal H. (2010). Adrenomedullin is increased in alveolar macrophages and released from the lungs into the circulation in severe heart failure. Basic Res Cardiol 105:89-98.
103. Pacher R, Stanek B, Hülsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G. (1996). Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 27:633-641. (Pubitemid 26081922)
104. Parkes DG, Vaughan J, Rivier J, Vale W, May CN. (1997). Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol 272: H2115-H2122.
105. Peterson JT, Li H, Dillon L, Bryant JW. (2000). Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 46:307-315. (Pubitemid 30204603)
106. Petrie M, McMurray J. (2001). Changes in notions about heart failure. Lancet 358:432-434. (Pubitemid 32769843)
107. Plaksej R, Kosmala W, Frantz S, Herrmann S, Niemann M, Störk S, Wachter R, Angermann CE, Ertl G, Bijnens B, Weidemann F. (2009). Relation of circulating markers of fbrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. J Hypertens 27:2483-2491.
108. Podrez EA, Schmitt D, Hof HF, Hazen SL. (1999). Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 103:1547-1560.
109. Poniatowski B, Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Dobrzycki S. (2009). Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in patients with chronic heart failure and coronary artery disease. Kidney Blood Press Res 32:77-80.
110. Potocki M, Breidthardt T, Reichlin T, Morgenthaler NG, Bergmann A, Noveanu M, Schaub N, Uthof H, Freidank H, Buser L, Bingisser R, Christ M, Mebazaa A, Mueller C. (2009). Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratifcation of patients with acute dyspnea: An observational study. Crit Care 13:R122.
111. Pousset F, Masson F, Chavirovskaia O, Isnard R, Carayon A, Golmard JL, Lechat P, Tomas D, Komajda M. (2000). Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J 21:1009-1014. (Pubitemid 30312090)
112. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM. (2005). Four-day urocortin-I administration has sustained benefcial haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J 26:2055-2062. (Pubitemid 41435727)
113. Rehman SU, Mueller T, Januzzi JL Jr. (2008). Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 52:1458-1465.
114. Reichlin T, Socrates T, Egli P, Potocki M, Breidthardt T, Arenja N, Meissner J, Noveanu M, Reiter M, Twerenbold R, Schaub N, Buser A, Mueller C. (2010). Use of myeloperoxidase for risk stratifcation in acute heart failure. Clin Chem 56:944-951.
115. Rudolph V, Baldus S. (2010). Myeloperoxidase for guiding therapy for acute cardiac decompensation? It's heart to tell. Clin Chem 56:881-882.
116. Ruiz-Ruiz FJ, Ruiz-Laiglesia FJ, Lasierra-Diaz P, Samperiz-Legarre P, Morales-Rull JL, Sánchez-Marteles M, Amores M, Perez-Calvo JI. (2007). Lack of clinical usefulness of interleukin-6 in long-term follow-up of acutely decompensated heart failure. Singapore Med J 48:532-536. (Pubitemid 351235356)
117. Ruiz-Ruiz FJ, Ruiz-Laiglesia FJ, Samperiz-Legarre P, Lasierra-Diaz P, Flamarique-Pascual A, Morales-Rull JL, Perez-Calvo JI. (2007). Propeptide of procollagen type I (PIP) and outcomes in decompensated heart failure. Eur J Intern Med 18:129-134. (Pubitemid 46330780)
118. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. (1997). Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 95:169-175. (Pubitemid 27029959)
119. Ruskoaho H. (2003). Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 24:341-356. (Pubitemid 36724374)
120. Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, Newman AB, Siscovick D, Shlipak MG; Cardiovascular Health Study. (2005). Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 142:497-505.
121. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J. (2007). Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 18:407-413. (Pubitemid 46193306)
122. Serradeil-Le Gal CJ, Wagnon J, Valette G, Garcia G, Pascal M, Mafrand JP, Le Fur G. (2002). Nonpeptide vasopressin receptor antagonists: Development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res 139:197-210. (Pubitemid 35460890)
123. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM. (2004). Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110:3121-3128. (Pubitemid 39492008)
124. Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, Satterfeld S, Cummings SR, Newman AB, Fried LF. (2006). Cystatin C and mortality risk in the elderly: The health, aging, and body composition study. J Am Soc Nephrol 17:254-261.
125. Shrestha KRW, Troughton RW, Borowski AG, Klein AL, Tang WHW. (2010). Relation of plasma neutrophil gelatinase-associated lipocalcin (NGAL) levels with myocardial function and prognosis in patients with chronic systolic heart failure. J Am Coll Cardiol 55.
126. Singer AJ, Birkhahn RH, Guss D, Chandra A, Miller CD, Tifany B, Levy P, Dunne R, Bastani A, Tode HC Jr, Hollander JE. (2009). Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): A randomized controlled trial of the effect of serial B-type natriuretic peptide testing on patient management. Circ Heart Fail 2:287-293.
127. Singh N, Dhalla AK, Seneviratne C, Singal PK. (1995). Oxidative stress and heart failure. Mol Cell Biochem 147:77-81.
128. Spinale FG. (2002). Matrix metalloproteinases: Regulation and dysregulation in the failing heart. Circ Res 90:520-530. (Pubitemid 34640901)
129. Spinale FG. (2007). Myocardial matrix remodeling and the matrix metalloproteinases: Infuence on cardiac form and function. Physiol Rev 87:1285-1342. (Pubitemid 350041472)
130. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ. (2000). A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102:1944-1949.
131. Stoiser B, Mörtl D, Hülsmann M, Berger R, Struck J, Morgenthaler NG, Bergmann A, Pacher R. (2006). Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 36:771-778. (Pubitemid 44569965)
132. Sundström J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, Sutherland P, Wilson PW, Vasan RS. (2004). Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: The Framingham Heart Study. Circulation 109:2850-2856. (Pubitemid 38786446)
133. Suttner SW, Boldt J. (2004). Natriuretic peptide system: Physiology and clinical utility. Curr Opin Crit Care 10:336-341. (Pubitemid 39313501)
134. Suzuki T, Solomon C, Jenny NS, Tracy R, Nelson JJ, Psaty BM, Furberg C, Cushman M. (2009). Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: The Cardiovascular Health Study. Circ Heart Fail 2:429-436.
135. Takano H, Hasegawa H, Nagai T, Komuro I. (2003). Implication of cardiac remodeling in heart failure: Mechanisms and therapeutic strategies. Intern Med 42:465-469. (Pubitemid 36926806)
136. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson RH, Apple FS, Ravkilde J, Wu AH; National Academy of Clinical Biochemistry Laboratory Medicine. (2007). National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 116:e99-e109. (Pubitemid 47450268)
137. Tang WH, Katz R, Brennan ML, Aviles RJ, Tracy RP, Psaty BM, Hazen SL. (2009). Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. Am J Cardiol 103:1269-1274.
138. Tang WH, Shrestha K, Martin MG, Borowski AG, Jasper S, Yandle TG, Richards AM, Klein AL, Troughton RW. (2010). Clinical signifcance of endogenous vasoactive neurohormones in chronic systolic heart failure. J Card Fail 16:635-640.
139. Tang WH, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, Jasper S, Hazen SL, Klein AL. (2007). Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 49:2364-2370. (Pubitemid 46891707)
140. Tomas JT, Kelly RF, Tomas SJ, Stamos TD, Albasha K, Parrillo JE, Calvin JE. (2002). Utility of history, physical examination, electrocardiogram, and chest radiograph for diferentiating normal from decreased systolic function in patients with heart failure. Am J Med 112:437-445. (Pubitemid 34450703)
141. Tsutamoto T, Nishiyama K, Sakai H, Tanaka T, Fujii M, Yamamoto T, Yamaji M, Horie M. (2008). Transcardiac increase in norepinephrine and prognosis in patients with chronic heart failure. Eur J Heart Fail 10:1208-1214.
142. Tsutsui T, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Ohnishi M, Kinoshita M. (2002). Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 39:957-962. (Pubitemid 34234116)
143. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM. (2006). Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48:1217-1224. (Pubitemid 44345127)
144. Vaz Pérez A, Doehner W, von Haehling S, Schmidt H, Zimmermann AV, Volk HD, Anker SD, Rauchhaus M. (2010). The relationship between tumor necrosis factor-a, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int J Cardiol 141:39-43.
145. Verma S, Szmitko PE, Yeh ET. (2004). C-reactive protein: Structure afects function. Circulation 109:1914-1917. (Pubitemid 38544477)
146. Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, Bergmann A, Squire I, van Veldhuisen DJ, Dickstein K; OPTIMAAL Investigators. (2009). C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: Results from the OPTIMAAL study. Eur Heart J 30:1187-1194.
147. Vredevoe DL, Widawski M, Fonarow GC, Hamilton M, Martínez-Maza O, Gage JR. (2004). Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure. Am J Cardiol 93:1007-1011. (Pubitemid 38479455)
148. Wada K, Tahara A, Arai Y, Aoki M, Tomura Y, Tsukada J, Yatsu T. (2002). Efect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction. Eur J Pharmacol 450:169-177. (Pubitemid 35232243)
149. Wang Y, Zhou Y, Meng L, Lu X, Ou N, Li X. (2009). Infammatory mediators in Chinese patients with congestive heart failure. J Clin Pharmacol 49:591-599.
150. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT. (2002). Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106:2961-2966. (Pubitemid 35424749)
151. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. (2003). Identifcation of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107:721-726. (Pubitemid 36222600)
152. Wiley CL, Switzer SP, Berg RL, Glurich I, Dart RA. (2010). Association of B-type natriuretic peptide levels with estimated glomerular fltration rate and congestive heart failure. Clin Med Res 8:7-12.
153. Wright SP, Doughty RN, Frampton CM, Gamble GD, Yandle TG, Richards AM. (2009). Plasma urocortin 1 in human heart failure. Circ Heart Fail 2:465-471.
154. Xue Y, Shah AM, Maisel AS. (2010). Increased 90-day mortality in patients with elevated copeptin: Secondary results from biomarkers in acute heart failure (BACH) study. J Am Coll Cardiol 55.
155. Yang DC, Ma ST, Tan Y, Chen YH, Li D, Tang B, Chen JS, Su XH, Li G, Zhang X, Yang YJ. (2010). Imbalance of matrix metalloproteinases/ tissue inhibitor of metalloproteinase-1 and loss of fbronectin expression in patients with congestive heart failure. Cardiology 116:133-141.
156. Yeh ET, Willerson JT. (2003). Coming of age of C-reactive protein: Using infammation markers in cardiology. Circulation 107:370-371.
157. Zalewski A, Macphee C, Nelson JJ. (2005). Lipoprotein-associated phospholipase A2: A potential therapeutic target for atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 5:527-532. (Pubitemid 43008525)
158. Zhang R, Brennan ML, Shen Z, MacPherson JC, Schmitt D, Molenda CE, Hazen SL. (2002). Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of infammation. J Biol Chem 277:46116-46122. (Pubitemid 35417600)